Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo and Penwest settle litigation with Actavis
Endo and Penwest have agreed to dismiss their suit with prejudice and Actavis has agreed to dismiss its counterclaims with prejudice. Under the terms of the settlement, Endo
Endo and Penwest have agreed to dismiss their suit with prejudice and Actavis has agreed to dismiss its counterclaims with prejudice. Under the terms of the settlement, Endo
And his recent chairmanships include Synexus Clinical Research plc, Arakis Ltd and Mircroscience Ltd. His executive career began at Glaxo Group plc in 1967 and was followed, from
Full Year 2008 & Recent Highlights: Global revenues were $128 million, an 8.5% increase year over year Domestic revenues grew 7% to $109 million International revenues grew 19%
Under terms of the agreements, Vista has secured the exclusive, worldwide rights for the use of nanowires for the detection of biomarkers associated with organ or tissue damage,
The approval satisfies the condition to the tender offer related to European Commission regulatory approval and is the last regulatory approval that is a condition to the tender
Mr Whelan replaces Gregory Turnbull, who was serving as interim CFO and will remain a company director and a member of the board’s executive committee. Prior to joining
The FDA has previously approved this improved formulation of Epoprostenol for Injection (1.5mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with
Designed as a close research collaboration, the ‘Sanofi-Aventis Regenerative Medicine Program’ at the Salk Institute will support the institute’s stem cell facility, for up to five years, and
Through the partnership, GE Healthcare will certify HCL on its core healthcare IT offering Centricity Enterprise and integrate HCL into its Digital Day One effort which helps new
Particle Sciences said that it has already used the system to develop an ocular formulation for one of its clients. Early clinical results are very promising but are